Fig. 1: Best RECIST response and time on study in Module 1A. | Nature Communications

Fig. 1: Best RECIST response and time on study in Module 1A.

From: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Fig. 1

A Best response. Each bar represents the best percentage change from baseline for an individual patient and labels indicate the best objective response for the same patient. N = 30 (Note: only participants with measurable lesions at both baseline and post-baseline are included in this figure). BID = twice daily; OD = once daily; PD = progressive disease; PR=partial response; SD = stable disease. B Time on study. Each bar is annotated with the ___location of the primary malignancy for each participant.Only patients with measurable lesions at both baseline and post-baseline are included in the figure. N = 36. BID twice daily, CR complete response, OD once daily, PD progressive disease, PR partial response, SD stable disease.

Back to article page